AKT1 and glioblastoma: Inhibitors of the calcineurin-NFAT pathway suppressed proto-oncogenic pathways (hypoxia, glycolysis, PI3K/AKT/mTOR signaling axis) in vivo in GBM and, consequently, are being considered for therapies [48].